Table 4.
Primary invasive cancer incidence in GH-treated and non GH-treated patients from the USA. SIRs were calculated using SEER data (24).
| Treatment group | Observed cases | Expected cases | SIR (95% CI) |
|---|---|---|---|
| GH-treated (n=3165) | 71 | 75.79 | 0.94 (0.73–1.18) |
| Non GH-treated (n=631) | 27 | 23.28 | 1.16 (0.76–1.69) |
CI, confidence interval; SIR, standardized incidence ratio.